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Structured Abstract
Objective: The aim of this study was to determine if VATS and robotic-assisted lobectomy
(RL) were associated with a reduction in length of stay and overall complication rate
compared to open lobectomy (OL).
Summary Background Data: Robotic-assisted lobectomy has seen increasing adoption for
treatment of early-stage lung cancer. Comparative data regarding these approaches is largely
from single-institution case series or administrative datasets.
Methods: Retrospective data was collected from 21 institutions from 2013-2019. All
consecutive cases performed for clinical stage IA-IIIA lung cancer were included.
Neoadjuvant cases were excluded. Propensity-score matching (1:1) was based on age, gender,
race, smoking-status, FEV1%, Zubrod score, ASA score, tumor size and clinical T and N
stage.
Results: A total of 2,391 RL, 2,174 VATS, and 1,156 OL cases were included. After
propensity-score matching there were 885 pairs of RL vs. OL, 1,711 pairs of RL vs. VATS,
and 952 pairs of VATS vs. OL. Operative time for RL was shorter than VATS (p <0.0001)
and OL (p=0.0004). Compared to OL, RL and VATS had less overall postoperative
complications, shorter hospital stay (LOS), and lower transfusion rates (all p< 0.02).
Compared to VATS, RL had lower conversion rate (p < 0.0001), shorter hospital stay (p <
0.0001) and a lower postoperative transfusion rate (p=0.01). RL and VATS cohorts had
comparable postoperative complication rates. In-hospital mortality was comparable between
all groups.

Conclusions: RL and VATS approaches were associated with favorable perioperative
outcomes compared to OL. Robotic-assisted lobectomy was also associated with a reduced
length of stay and decreased conversion rate when compared to VATS.
Mini-Abstract
Peri-operative outcomes of robotic-assisted, VATS, and open lobectomy for lung cancer were
retrospectively reviewed from 21 US centers between 2013-19. Using propensity-score
matching, robotic-assisted and VATS lobectomy were associated with reduced peri-operative
morbidity and a shorter length of stay compared to open lobectomy.

Introduction
Pulmonary lobectomy is a procedure which can be performed by three competing
approaches – video-assisted, robotic-assisted and open thoracotomy. There is no single
approach that is performed in a majority of cases in the United States [1, 2]. Open lobectomy
(OL) continues to be routinely performed despite publications suggesting VATS lobectomy is
associated with reduced complications compared to OL, and guidelines recommending
VATS as the preferred approach for early-stage lung cancer [3-5]. Robotic-assisted
lobectomy (RL) is a newer modality, and its adoption has grown rapidly from less than 1% of
lobectomies in 2008 to 18% by 2015 [2,6]. Debate persists on whether there is an optimal
approach.
Comparative data on the efficacy of these approaches have largely come from single
institutions or administrative datasets [1,2,6-11]. While databases may reflect real-world data,
there is no ideal database, and none contain all of the information of interest to clinicians. For
instance, The Society of Thoracic Surgery database has excellent perioperative data but no
information on cancer-related outcomes. In contrast, the National Cancer Database has
granular oncologic data but little information on perioperative outcomes. Administrative
databases such as the National Inpatient Sample and Premier are based on ICD coding with
their attendant limitations.
The present study was designed to be a large, multi-center retrospective study to
assess outcomes for all three lobectomy techniques from experienced surgeons. The aim was
to compare the perioperative outcomes at a large scale with sufficient granular data that could
not be accomplished by single-institution studies or databases. We hypothesized that a
minimally invasive approach to lobectomy would be associated with a reduction in length of
stay and overall complication rate compared to open thoracotomy.

Methods
Data Sources
Retrospective data was collected from 21 centers in the United States (Supplemental
Table 1, http://links.lww.com/SLA/D312). Centers with specific expertise in RL, VATS
and/or OL participated. Three surgeons with significant experience in RL (MSK), VATS
(MH) and OL (EV) were designated as co-chairs to conduct this study.
To ensure adequate experience, participating surgeons were required to have
performed at least 50 total lobectomies prior to case submission. Data from all consecutive
lobectomies for clinical stage IA-IIIA lung cancer from January 2013 to 30-days prior to
institutional review board (IRB) approval at each center were included. Chart review and data
collection were performed in a reverse chronological order in accordance with the IRB
guidelines. De-identified data was retrieved using standardized electronic data collection
forms to ensure uniformity. A study-specific informed consent waiver for retrospective data
collection was obtained from each institution’s IRB. Information from all patients was
maintained confidential and managed according to the requirements of the Health Insurance
Portability and Accountability Act of 1996. Data collection closed for all centers on June 21,
2019.
Emergency cases, indications other than lung cancer, bi-lobectomies, and sleeve
lobectomies were excluded from analysis. Data was collected on demographics, clinical and
pathologic staging, induction therapy, operative details including conversions, peri-operative
complications as well as overall and cancer-specific survival. Data on peri-operative
mortality and complications was collected from the in-hospital stay as well as the last followup within 90 days. Operative time was inclusive of docking time for robotic cases. Data
regarding induction therapy, pathologic staging, and survival will be examined in future
analyses.
Data analysis was performed on an intent-to-treat basis. Consequently, conversions
were analyzed under the initial operative approach, regardless of the reason for conversion.
Conversions were categorized as elective due to failure to progress or emergent due to lifethreatening hemorrhage. Conversions in the RL cohort included conversions to VATS as well
as to thoracotomy. All major complications and conversions were independently reviewed by
the site’s principal investigator to ensure data integrity. Operative and pathology reports and
discharge summaries were also randomly audited from 40% of cases to verify accuracy.
Statistical Analysis
Standard univariate and bivariate techniques were used to describe the clinical results.
Continuous variables were defined as means (and standard deviations), median, first and third
quartiles. Discrete variables (i.e., conversions, complications) were described as rates and
proportions of the totals. All statistical analyses was performed by an independent statistician.

A propensity-score model for adjustment of baseline variables was implemented to
decrease bias between groups. Comparisons were made for RL versus OL, VATS versus OL,
and RL versus VATS. Propensity score-adjusted comparisons were calculated by fitting a
multivariable logistic regression analysis. A one-to-one nearest neighbor matching algorithm
was applied using a caliper of 0.10. Controls were not re-used during matching. Covariates
used for matching were age, gender, race, smoking status, American Society of
Anesthesiologists (ASA) grade, Zubrod score, FEV1 %, tumor size category ( 3cm, 3-7cm
and 7cm), clinical T stage, and clinical N stage. Standardized differences and histograms of
propensity score before and after matched were used to evaluate effectiveness of the
matching procedure to balance the populations on the covariates.
RL, VATS, and OL cohorts were compared using standard statistical tests appropriate
for paired comparisons. McNemar’s test was used for categorical variables, paired t-test for
continuous approximately normally distributed variables, and Wilcoxon signed rank test for
ordinal and significantly non-normally distributed continuous variables. The Kaplan-Meier
method was used to calculate survival rates at 30 days in order to account for subjects
censored prior to 30 days. The stratified log rank test was used to compare the survival
through 30 days and to account for the paired nature of the data. A p-value of less than 0.05
was considered statistically significant.
All analyses, with the exception of PSM, were performed in SAS version 9.4. The
PSM was performed in R version 3.5.2 using the Matchit package.
Results
Baseline Characteristics
A total of 6,216 lobectomy patients (2,557 RL, 2,324 VATS, and 1,335 OL) were
reviewed. Patients who underwent induction therapy were excluded, leaving 2,391 RL, 2,174
VATS, and 1,156 OL cases. PSM allowed three pairwise comparisons: RL vs. OL (n=885
each), VATS vs. OL (n=952 each), and RL vs. VATS (n=1,711 each) (Figure 1). Summary
statistics for the three groups at baseline prior to matching are shown in Supplemental Table
2, http://links.lww.com/SLA/D312. After matching, there were no significant differences
between baseline characteristics between cohorts, with the exception of Zubrod score in some
comparisons (Supplemental Table 3, http://links.lww.com/SLA/D312). Standardized
difference plots and mirror histograms also demonstrated balanced groups following
propensity matching (Supplemental Figures 1-6, http://links.lww.com/SLA/D313). While
mean tumor size was also statistically different among some groups by up to 3 mm, T stage,
N stage, and TNM stage were comparable across all groups.
Intraoperative Outcomes: Propensity-Matched Analysis
Pairwise comparisons of intraoperative characteristics are presented in Supplemental
Table 4, http://links.lww.com/SLA/D312. Mean operating-room (OR) time (wheels-in to

wheels-out) was analyzed by excluding cases that included a concomitant procedure such as a
mediastinoscopy or additional lung resection. In cases with no concomitant procedures, there
was a statistically shorter OR time for the RL cohort compared to both OL and VATS
cohorts. OR time for the VATS cohort was 20 minutes longer than for the OL cohort
(p=0.01).
The conversion rate was also lower in RL cases compared to VATS (Figure 2a). To
adjust for tumor characteristics that could influence conversion to thoracotomy, conversion
was analyzed based on stage. RL was associated with a lower conversion rate than VATS for
all clinical stages (Figure 2b). The majority of conversions were non-emergent in both
groups (Figure 2c).
Intraoperative estimated blood loss was statistically lower for both minimally invasive
approaches compared to OL. The intraoperative transfusion rate was also statistically lower
for both MIS approaches compared to open. Between the two MIS approaches, RL was
associated with less EBL compared to VATS but there was no statistical difference in
transfusion rates.
Post-operative Outcomes: Propensity-Matched Analysis
Both MIS approaches were associated with a lower rate of in-hospital and
postoperative complications compared to OL (Table). The most frequent complication in all
cohorts was pulmonary (including prolonged air leak, pneumonia and need for
bronchoscopy). The overall rate of pulmonary complications was significantly lower for both
MIS approaches when compared to open. No difference in pulmonary or overall morbidity
was observed between the robotic and VATS cohorts.
Unexpected returns to the OR were similar among all operative approaches. Postoperative transfusions were less frequent with RL versus OL and RL versus VATS. Median
LOS was also significantly different among groups. Prolonged LOS (>7 days) was also
significantly lower among the RL group compared to both OL and VATS groups. Similarly,
significant differences in chest tube duration were also observed among the three groups. No
significant differences in in-hospital mortality were observed among the three operative
approaches. Mortality at 30-days was below 1% and was equivalent among groups.
Stratification of the propensity-matched data by tumor location did not impact any
perioperative outcomes such as conversion rate, length of stay, overall morbidity or mortality.
Discussion
In this study, a minimally invasive approach to lobectomy was associated with
significant reductions in peri-operative morbidity, lower transfusion rate, and lower LOS
compared to OL. These findings are concordant with several previous publications, which
have documented a reduction in morbidity and length of stay with both VATS and RL
compared to OL [2,4,6,12,13].

A direct comparison of outcomes between VATS and RL is of particular interest
given current clinical practice trends. Previous publications based on national databases have
reported conflicting results. For instance, in a review of The Society of Thoracic Surgeons
database from 2009-2013, morbidity, mortality, and length of stay were comparable between
both approaches [14]. Similar findings were also observed in a recent analysis of the
Surveillance, Epidemiology and End-Results Medicare database [9]. In contrast, other recent
publications have suggested that RL is associated with improvements in clinically relevant
outcome measures compared to VATS. For instance, two publications analyzing the Premiere
database observed a reduced conversion rate, overall complication rate, and shorter LOS with
RL [2,15]. Furthermore, a recent meta-analysis of 14 studies demonstrated statistically
significant reductions in conversion and mortality rates with RL compared to VATS [16]
In the current study, we observed differences in outcomes between the two minimally
invasive approaches. RL was associated with a shorter operative time, suggesting that with
experienced teams, robotic cases are not inherently longer than VATS. In the postoperative
period, RL was associated with shorter chest tube duration and LOS compared to VATS.
There were also fewer patients in the RL cohort with a prolonged LOS (>7 days). However,
there was no difference in overall complications or mortality between RL and VATS.
The difference in conversion rates between RL and VATS was unexpected given that
both groups had similar patient and stage characteristics after matching. The higher
conversion rate in VATS was due to failure to progress during the case, as opposed to
hemorrhage. It is possible that surgeons in the RL group only scheduled cases they were
confident could be done robotically since the robotic system had to be scheduled in advance,
whereas VATS surgeons may have considered starting any case thoracoscopically as a
relatively low-risk approach. However, the observation that the conversion rate was lower in
the RL group for every clinical stage suggests that there could be advantages with the robotic
system during more difficult dissection.
A strength of this study is that we analyzed cases performed up to 2019, in contrast to
previous database studies which did not include cases beyond 2015 [1,2,9]. The inclusion of
more recent cases is important for two reasons: 1) surgeons collectively will have greater
experience with the robotic procedure and 2) the latest generation robotic platform was
introduced in 2014 and has several technological advancements over the previous platform.
We believe the inclusion of more recent cases allows a suitable comparison to the wellestablished alternatives of VATS and open lobectomy. We also mitigated possible bias by
including only surgeons who were beyond their learning curve for each particular surgical
approach.
However, there are important limitations to the present data. Although we performed
a propensity-matched and intention-to-treat analysis, there are selection biases in a
retrospective study that cannot be entirely overcome with statistical methods. For example,
the higher transfusion rate in the OL group may reflect differences in tumor characteristics
not accounted for by propensity score matching. Furthermore, variability between

institutions, such as training of operating room personnel and the use of enhanced recovery
after surgery programs may have an impact on operative times and LOS, independent of the
operative approach utilized [17]. Every center had different postoperative patient
management protocols, making LOS difficult to interpret. In addition, participation of
trainees in the case may also have had an impact on operative time.
Other limitations in this multicenter retrospective study should also be acknowledged.
For example, factors such as the cumulative lobectomy volume of individual surgeons and
institutions, as well as the specific case volume on each platform would be expected to have
an impact on outcomes. However, this data was not collected and consequently was not
considered in the propensity-matched analysis. In addition, we should note that we only
reported in-hospital complication rates, rather than the gold-standard 30 and 90-day rates. In
part this was due to the variable follow-up of patients across surgeons and institutions, and
thus patients were not consistently assessed at 30 and 90 days. In addition, we found that
centers did not always distinguish between complications which occurred in-hospital and
persisted following discharge versus new complications which developed after discharge. For
both of these reasons we therefore reported in-hospital complication rates only in this
analysis.
Importantly, the sponsorship of this study by industry and the potential for reporting
bias should be discussed. We acknowledge that the concern for potential bias can never be
completely mitigated. However, we feel that it is important to emphasize the measures
undertaken to reduce such bias and maintain data integrity, and to place this study in the
larger context of other studies performed on this subject.
To reduce bias, sites with recognized expertise in VATS and open lobectomy were
invited to participate in this study, and co-chairs from these institutions were selected to
provide oversight on data integrity. Furthermore, institutions were required to submit data on
all consecutive lobectomy cases during the study period, regardless of operative approach.
Consequently, it is not the case that an institution with a high volume of robotic cases only
submitted data on those cases while excluding open and VATS procedures.
Measures were also instituted to maintain integrity of the dataset. Nearly half of the
cases were audited and compared to imaging and pathology reports to ensure accuracy.
Similarly, all conversions to open thoracotomy were reviewed to document that the
conversion was unplanned and to verify the reason for conversion. Additionally, outcome
measures were analyzed based on the initial operative approach regardless of the reason for
conversion. Furthermore, statistical analysis was performed by an independent biostatistician.
Importantly, we should also emphasize that collection of data was independently undertaken
by investigators at each institution. While this does not eliminate bias, it is not the case that
outcome data was submitted and extracted by industry representatives. The investigators at
each site, regardless their personal experience in robotic, VATS or open lobectomy were
responsible for data accuracy and submission.

Finally, while acknowledging the potential for bias we should also note that the
findings in this study are concordant with previous publications. We observed no difference
in mortality or morbidity between the VATS and robotic cohorts, and the reduction in length
of stay and conversion rates in the robotic cohort has been observed in prior studies.
Certainly, a randomized controlled trial comparing VATS, robotic-assisted and open
lobectomy would provide more clarity on this topic. However, such a study would be very
difficult to undertake in the United States. Issues of patient preference notwithstanding, many
surgeons with minimally invasive experience are not equally skilled in both VATS and
robotic-assisted procedures. As such it would be difficult to randomize patients to one
approach over the other while ensuring the highest quality surgical care. In addition, financial
considerations for such a study would pose a significant barrier outside of industry
sponsorship. Given these limitations, we feel that the present design of a large-scale,
multicenter retrospective study may provide the best source of information to guide clinical
decision making at present.
In summary, in this retrospective multi-institutional data analysis, both RL and VATS
lobectomy were associated with improved peri-operative outcomes compared to OL. RL was
associated with additional differences compared to VATS, such as a reduced length of stay
and conversion rate. The specific etiology of these differences requires further investigation.
As additional cases are collected, more granular analysis of conversions, cost-modeling, and
cancer outcomes are planned.
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Figure Legends
Figure 1: Flowchart for propensity-matched analysis

Figure 2: Conversions from minimally invasive to open lobectomy. Panel A: Overall
conversion rate by approach. Panel B: Conversion rate by clinical stage. Panel C: Reason for
conversion.

Table 1. Propensity-matched pairwise comparisons of postoperative details prior to patient discharge
outcomes for RL, VATS, and OL cases.

Variable

Complications,
n (%)
Pulmonary
Cardiac
Gastrointesti
nal
Neurological
Wound
Genitourinar
y
Unexpected
return to
operating
rooma, n (%)
Post-operative
blood
transfusion, n
(%)
Chest tube
durationa, d
(±SD)
Length of
hospital stay,
Mean d (±SD)
Median d
Prolonged
length of
hospital stay
(>7days), d
(±SD)
In-hospital
mortality, n (%)
b, c

RL versus OL

VATS versus OL

RL
(n=88
5)
237
(26.8)

OL
(n=88
5)
315
(35.6)

pvalue

RL
(n=171
1)
463
(27.1)

VATS
(n=171
1)
511
(29.9)

pvalue

156
(17.6)
83
(9.4)
8 (0.9)

198
(22.4)
125
(14.1)
6 (0.7)

333
(19.5)
187
(10.9)
20 (1.2)

0.20

0.35

304
(17.8)
169
(9.9)
13 (0.8)

12
(1.4)
1 (0.1)

17
(1.9)
2 (0.2)

0.34

18
(1.9)
3 (0.3)

0.72

24 (1.4)

25 (1.5)

0.88

1.00

5 (0.3)

4 (0.2)

0.74

31
(3.5)

15
(1.7)

0.02

33
(3.5)

17
(1.8)

0.01

66 (3.9)

77 (4.5)

0.35

25
(2.9)

27
(4.9)

0.15

37
(4.3)

31
(5.3)

0.32

50 (3.0)

66 (4.2)

0.14

13
(1.5)

67
(7.6)

<0.000
1

24
(2.5)

77
(8.1)

<0.000
1

22 (1.3)

42 (2.5)

0.01

3.8±5.
2

5.2±5.
2

<0.000
1

4.3±4.
7

5.3±5.
3

<0.000
1

4.0±5.5

4.4±5.1

<0.000
1

4.2±4.
9

6.1±4.
9

<0.000
1

5.1±4.
4

6.1±6.
4

<0.000
1

4.1±4.4

5.2±4.6

<0.000
1

3

5

4

5

3

4

77
(8.7)

157
(18.2)

<0.000
1

151
(15.9)

169
(18.2)

0.29

150
(8.8)

275
(16.1)

<0.000
1

3 (0.3)

7 (0.8)

0.21

4 (0.4)

7 (0.7)

0.37

8 (0.5)

7 (0.4)

0.80

<0.000
1
0.01
0.002
0.59

0.56

VATS
(n=95
2)
266
(27.9)

OL
(n=95
2)
339
(35.6)

170
(17.9)
102
(10.7)
11
(1.2)
15
(1.6)
2 (0.2)

214
(22.5)
141
(14.8)
8 (0.8)

pvalue

RL versus VATS

0.001
0.01
0.03

0.07

0.32
0.22

